Fidelity Investments
NRIX icon

Fidelity Investments’s Nurix Therapeutics NRIX Stock Holding History

Fidelity Investments’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$85.9M Buy
5,541,271
+1,307,113
+31% +$21.7M ﹤0.01% 1242
2025
Q4 		$80.3M Sell
4,234,158
-4,653,379
-52% -$66.8M ﹤0.01% 1269
2025
Q3 		$82.1M Sell
8,887,537
-1,554,930
-15% -$16.1M ﹤0.01% 1262
2025
Q2 		$119M Buy
10,442,467
+110,256
+1% +$1.19M 0.01% 1045
2025
Q1 		$123M Sell
10,332,211
-302,020
-3% -$5.05M 0.01% 1005
2024
Q4 		$200M Buy
10,634,231
+10,047,329
+1,712% +$230M 0.01% 824
2024
Q3 		$13.2M Buy
586,902
+511,256
+676% +$11.6M ﹤0.01% 1839
2024
Q2 		$1.58M Buy
75,646
+4,284
+6% +$66.7K ﹤0.01% 2405
2024
Q1 		$1.05M Sell
71,362
-252,367
-78% -$2.71M ﹤0.01% 2488
2023
Q4 		$3.34M Buy
323,729
+2,822
+0.9% +$19.3K ﹤0.01% 2180
2023
Q3 		$2.52M Sell
320,907
-95,706
-23% -$874K ﹤0.01% 2225
2023
Q2 		$4.16M Sell
416,613
-33,631
-7% -$343K ﹤0.01% 2117
2023
Q1 		$4M Sell
450,244
-553,399
-55% -$5.77M ﹤0.01% 2158
2022
Q4 		$11M Sell
1,003,643
-682,008
-40% -$8.23M ﹤0.01% 1846
2022
Q3 		$22M Sell
1,685,651
-105,004
-6% -$1.66M ﹤0.01% 1580
2022
Q2 		$22.7M Buy
1,790,655
+668,632
+60% +$7.58M ﹤0.01% 1601
2022
Q1 		$15.7M Buy
1,122,023
+13,920
+1% +$247K ﹤0.01% 1902
2021
Q4 		$32.1M Buy
1,108,103
+449,486
+68% +$13.6M ﹤0.01% 1600
2021
Q3 		$19.7M Hold
658,617
– – ﹤0.01% 1855
2021
Q2 		$17.5M Buy
658,617
+79,532
+14% +$2.33M ﹤0.01% 1895
2021
Q1 		$18M Buy
579,085
+243,400
+73% +$9.21M ﹤0.01% 1840
2020
Q4 		$11M Hold
335,685
– – ﹤0.01% 1937
2020
Q3 		$11.7M Buy
+335,685
New +$8.46M ﹤0.01% 1773

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Fidelity Investments's NRIX Position: Q1 2026 in Review

Fidelity Investments increased its Nurix Therapeutics (NRIX) stake by 31% in Q1 2026, buying an estimated $21.7M and bringing the position to 5,541,271 shares worth $85.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1242.

Fidelity Investments first reported a position in NRIX in Q3 2020 and has held it in 23 quarters since. The position peaked at $200M in Q4 2024. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Fidelity Investments held 5,541,271 shares of Nurix Therapeutics worth $85.9M as of Q1 2026.
  • Fidelity Investments bought 1,307,113 Nurix Therapeutics shares in Q1 2026, an estimated $21.7M.
  • Nurix Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #1242 holding.
  • Fidelity Investments first reported a position in Nurix Therapeutics in Q3 2020 and has held it in 23 quarters since.
  • Fidelity Investments's Nurix Therapeutics position peaked at $200M in Q4 2024.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.